Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Zug, Switzerland (ots/PRNewswire) -

- The expanded partnership will allow Alnylam and Medison to help accelerate
access for patients in multiple regions under one global alliance
- Medison, the creator and leader of the multi-regional partnership category,
will utilize its unique, unified platform for efficient global
commercialization of Alnylam's innovative RNAi technologies

Medison Pharma (https://www.medisonpharma.com/) ("Medison"), a global pharma
company focused on providing access to highly innovative therapies for patients
in international markets, and Alnylam Pharmaceuticals, Inc.
(http://www.alnylam.com/) (Nasdaq: ALNY), the leading RNAi therapeutics company,
announced today a further expansion of their existing partnership in Central &
Eastern Europe and Israel, to also include selected markets in LATAM and APAC
and additional international markets.

Medison, the creator and leader of the multi-regional partnership category, has
established a unique, unified commercialization platform in international
markets, particularly for the treatment of rare and severe diseases. Medison is
the only partner that focuses solely on the most innovative therapies.

Alnylam and Medison initially partnered in 2018. Ever since, the partnership has
expanded to additional regions and markets, to ensure that Alnylam's commercial
therapies, such as ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI®
(givosiran), and OXLUMO® (lumasiran) are made available across multiple
international markets.

"We are delighted to extend yet again our existing partnership with Medison,
which will enable us to enhance our presence and bring the benefits of Alnylam's
innovative RNAi therapeutics to patients in additional APAC and LATAM markets,"
said Norton Oliveira, Senior Vice-President and Head of Partner and Emerging
Markets at Alnylam. "Medison is at the forefront of the global trend of
consolidating international markets under one alliance. Together, we'll provide
faster access to more patients around the world."

"The new category of the multi-regional partnerships that we have been creating
in the past few years continues to get traction with the most innovative biotech
companies," said Meir Jakobsohn, Founder and Executive Chairman of Medison. "We
are proud of our longstanding partnership with Alnylam and will continue to work
together to bridge geographical gaps, ensuring that Alnylam's life-saving
therapies reach patients in need."

"Our unified commercial platform enables biotech companies to transform numerous
complex and fragmented markets and regions into a unified territory, and we are
proudly leading the trend and the category," said Gil Gurfinkel, CEO of Medison.